Benefits
Lipase and α-Amylase Inhibition (Fat and Carb Blocking)
ID-alG™ inhibits two main digestive enzymes — pancreatic lipase (fat digestion) and α-amylase (starch digestion). Reduces absorption of dietary fats and carbohydrates. >50% enzyme inhibition guaranteed. Foundational mechanism.
Weight Loss with Body Composition Improvement
Nexira clinical study showed significant weight loss correlated with fat mass reduction; decreased abdominal and visceral fat; significant reduction in carb assimilation and HbA1c (glycated hemoglobin). Established in target demographic.
HbA1c Reduction
Reduction in glycated hemoglobin reflects improved long-term glucose control. Mechanism: reduced carbohydrate absorption from α-amylase inhibition + reduced glucose excursions over time. Modest but meaningful for metabolic health.
Body Shape Improvement
Reduction of abdominal and visceral fat — visible body shape improvement beyond just weight loss. Particularly relevant for older women's body composition concerns.
User Satisfaction Validation
Nexira survey: 76% convinced of weight management effect; 72% would continue using ID-alG™. High user satisfaction reflects perceived efficacy and tolerability.
Mechanism of action
Phlorotannin Enzyme Inhibition
Phlorotannins (marine polyphenols specific to brown algae; structurally similar to terrestrial tannins but distinct chemistry) inhibit pancreatic lipase and α-amylase via enzyme-substrate competitive inhibition. Reduces digestion/absorption of fats and starches.
Reduced Caloric Intake from Macronutrient Blocking
Lipase inhibition reduces fat absorption; α-amylase inhibition reduces starch absorption. Net caloric reduction supports weight management. Same mechanism category as orlistat (pharmaceutical lipase inhibitor) but weaker effect with better tolerability.
Soluble Fiber Component
Ascophyllum nodosum also provides soluble fiber (alginates, fucoidan) — additional satiety and microbiome effects.
Iodine Content Consideration
Brown seaweeds naturally contain iodine; concentrated extracts have variable iodine content — Nexira processes for safe iodine levels in supplemental form. Verify product specifications.
Clinical trials
RCT of ID-alG™ on weight, body composition, and metabolic markers.
Adults with weight management concerns (women 45+ target).
Significant weight loss correlated with fat mass; decreased fat assimilation, body fat mass, abdominal/visceral fat; reduced carb assimilation and HbA1c; body shape improvement; no signs of discomfort.
Multiple studies of brown algae phlorotannins on enzyme inhibition and metabolic effects.
In vitro and clinical.
Established phlorotannin-mediated lipase and α-amylase inhibition; modest clinical metabolic effects. Foundation for evidence-based marine algae weight management applications.
About this ingredient
ID-ALG™ is a STANDARDIZED BROWN SEAWEED EXTRACT from ASCOPHYLLUM NODOSUM developed by NEXIRA (France) — designed to limit fat and sugar storage via marine polyphenol enzyme inhibition. ASCOPHYLLUM NODOSUM is a brown algae (Fucaceae family) found along ROCKY COASTS OF THE NORTH ATLANTIC, where it forms dense colonies; reaches up to 1.5 meters; manually harvested year-round; carefully selected in ocean and re-checked at processing facility.
KEY ACTIVE COMPOUND: PHLOROTANNINS (marine polyphenols specific to brown algae) — distinct from terrestrial polyphenols; derived from phloroglucinol units. ID-ALG™ DISTINCTIONS: (1) STANDARDIZED to >50% inhibition of lipase AND α-amylase (in tubo testing); (2) MANUALLY HARVESTED — sustainable wild-harvest; (3) PROCESSED IN FRANCE; (4) TARGETED for women 45+ weight management.
EVIDENCE-BASED USES: (1) WEIGHT LOSS with fat mass reduction (Nexira clinical study); (2) Reduced abdominal and visceral fat; (3) HbA1c REDUCTION (long-term glucose control improvement); (4) Body shape improvement; (5) Weight management adjunct.
MECHANISM CATEGORY: Lipase + α-amylase inhibitor — same general category as orlistat (Xenical, Alli) but weaker effect with better GI tolerability.
CRITICAL CAUTIONS: (1) IODINE CONTENT — brown algae naturally contain iodine; concentrated extracts may provide significant iodine; relevant for: (a) those with autoimmune thyroid disease (Hashimoto's, Graves'), (b) iodine-sensitive thyroid conditions, (c) those on thyroid medications, (d) pregnancy (excess maternal iodine can cause fetal thyroid dysfunction); verify product iodine content; (2) PREGNANCY/LACTATION — iodine concerns plus general weight loss inappropriateness in pregnancy; AVOID supplementation; (3) FAT MALABSORPTION — like orlistat, lipase inhibitors may cause: (a) loose stools, (b) reduced fat-soluble vitamin absorption — consider supplementing A, D, E, K or eating fat-containing meals at different times; (c) reduced absorption of fat-soluble medications; (4) HEAVY METAL CONTAMINATION — seaweeds can accumulate heavy metals (arsenic, cadmium, lead) from ocean; reputable processing tests for/removes; verify quality certifications; (5) DIABETES MEDICATIONS — additive hypoglycemic effects from reduced carb absorption; monitor blood glucose; (6) ANTICOAGULANTS — brown algae fucoidan has modest anticoagulant activity; theoretical bleeding risk; consult; (7) DOSE — 400 mg/day per Nexira recommendation; (8) ID-ALG™ VS ORLISTAT — both inhibit lipase; ID-alG much weaker, much better tolerated; orlistat has known significant GI side effects (oily stools, urgency, fat malabsorption); ID-alG provides modest version of same mechanism with much better tolerability; (9) WEIGHT MANAGEMENT FRAMEWORK — caloric deficit, exercise, behavior change foundational; ID-alG one tool; (10) FOR WOMEN 45+ — Nexira specifically targets this demographic; relevant for menopausal/perimenopausal weight gain (different physiology than younger weight gain); (11) METABOLIC HEALTH — HbA1c reduction reflects long-term glucose control improvement; relevant for prediabetes/diabetes prevention; (12) SUSTAINABILITY — wild-harvest with regulatory oversight (Atlantic algae fisheries); verify sustainable sourcing; (13) APPLICATIONS — food supplements (capsules typical); minimal sensory impact; (14) BRAND VERIFICATION — ID-alG™ is Nexira trademark; specific clinical evidence on this standardized form.